Skip to content
OpenCapital
Get started

Harmony Biosciences Holdings, Inc. HRMY Net debt / EBITDA

Net debt / EBITDA at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
5.6×-2.2×
Alkermes logo
AlkermesALKS
5.3×+4.7×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-2.8×—
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
-2.5×-3.9×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
-2.5×+0.4×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
0.2×-0.3×

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$1.98B-14.9%
Enterprise value$1.55B-24.9%
P/E13.6×-1.6×
P/S2.2×-0.9×

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Calculated from Harmony Biosciences Holdings, Inc.’s reported figures.

net debt/ebitda=-2×

Based on the most recent quarter.

The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harmony Biosciences Holdings, Inc.'s net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s net debt / EBITDA?
Harmony Biosciences Holdings, Inc. (HRMY) reported net debt / EBITDA of -2× in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s net debt / EBITDA changed year-over-year?
Harmony Biosciences Holdings, Inc.'s net debt / EBITDA decreased by 39.9% year-over-year, from -1.4× to -2×.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s net debt / EBITDA?
Over 5 years (2020 to 2025), Harmony Biosciences Holdings, Inc.'s net debt / EBITDA has grown at a 13.7% compound annual growth rate (CAGR), from -1.3× to -2.5×.
What does net debt / EBITDA mean?
Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.